Multimodal cytoreduction for carcinoid liver metastases: Analysis of a case series with highly advanced disease

European Surgery - Acta Chirurgica Austriaca

Volumn 40, Issue 2, 2008, Pages 72-76

  Sporn, E ^a   Mancini, G J ^a   Khajanchee, Y ^a   Wilson, Ch ^a   Hansen, P D ^a   Swanstrom, L L ^a   Thaler, Klaus ^a,b  

^a Minimally Invasive Surgery Program   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

Carcinoid disease; Hepatic metastasis; Multimodal cytoreduction; Survival; Symptom relief

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ANESTHESIA; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY;

EID: 43649093981     PISSN: 16821769     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10353-008-0395-z     Document Type: Article

References (22)

1. Moertel CG (1987) Karnofsky memorial lecture. An Odyssey in the land of small tumors. J Clin Oncol 5: 1502-1522
2. Norheim I, Oberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson A, Wide L, Wilander E (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206: 115-125
3. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229: 815-821; discussion 822-823
4. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130: 954-962
5. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK (2004) High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151: 107-112
6. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108: 1091-1096
7. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, Rikkers LF, Weber SM (2006) Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141: 1000-1004; discussion 1005
8. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241: 776-783; discussion 783-785
9. Bilchik AJ, Wood TF, Allegra D, Tsioulias GJ, Chung M, Rose DM, Ramming KP, Morton DL (2000) Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 135: 657-662; discussion 662-664
10. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y (1996) Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 20: 908-914; discussion 914-915
11. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169: 36-42; discussion 42-43
12. Siperstein AE, Berber E (2001) Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25: 693-696
13. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83: 2293-2301
14. O'Toole D, Maire F, Ruszniewski P (2003) Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 10: 463-468
15. Gehan EA, Tefft MC (2000) Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 92: 179-181
16. Kusaba H, Saijo N (2000) A summary report of response evaluation criteria in solid tumors (RECIST criteria). Gan To Kagaku Ryoho 27: 1-5
17. Sasaki T (2000) New guidelines to evaluate the response to treatment "RECIST". Gan To Kagaku Ryoho 27: 2179-2184
18. Knox CD, Feurer ID, Wise PE, Lamps LW, Kelly Wright J, Chari RS, Lee Gorden D, Wright Pinson C (2004) Survival and functional quality of life after resection for hepatic carcinoid metastasis. J Gastrointest Surg 8: 653-659
19. Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26: 985-990
20. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M, Ducreux M (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13: 136-140
21. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13: 572-581
22. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17: 600-606